Gilead Sciences director proposes $1.76M share sale

Available on EDGAR 11/12/2026 - 04:21 PM EST Accepted by SEC EDGAR 11/12/2026 - 04:21 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Kelly Kramer, a director of Gilead Sciences, Inc. (GILD), filed notice of a proposed sale of 10,376 common shares, with an aggregate market value of $1,761,118.48. The notice lists an approximate sale date of November 12, 2026. Kramer acquired the shares by exercising stock options and paying cash; the notice lists August 13, 2026 as the Rule 10b5-1 plan adoption or instruction date.

Key Figures

Proposed sale: 10,376 shares Aggregate market value: $1,761,118.48 Shares outstanding: 1,240,338,614 shares

3 metrics

Proposed sale 10,376 shares Common shares listed for sale by Kelly Kramer.

Aggregate market value $1,761,118.48 Value listed for the proposed sale.

Shares outstanding 1,240,338,614 shares Common shares outstanding as listed in the notice.

Key Terms

Rule 10b5-1, Exercise of Stock Options

2 terms

Rule 10b5-1 regulatory

"Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

Exercise of Stock Options financial

"Nature of Acquisition Transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many GILD shares did Kelly Kramer propose to sell?

Kelly Kramer, a director, reported a proposed sale of 10,376 common shares with an aggregate market value of $1,761,118.48; the approximate sale date is November 12, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001629885
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	GILEAD SCIENCE INC
SEC File Number	000-19731
Address of Issuer	333 Lakeside Drive Foster City CALIFORNIA 94404
Phone	6505743000
Name of Person for Whose Account the Securities are To Be Sold	KELLY KRAMER
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	10376	1761118.48	1240338614	11/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/12/2026	Exercise of Stock Options	Issuer			10376	11/12/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kelly Kramer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)